Detalles de la búsqueda
1.
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Kidney Int
; 99(3): 750-762, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33181154
2.
Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(8): 1968-1972, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33881796
3.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Circulation
; 139(3): 351-361, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586723
4.
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
Nephrol Dial Transplant
; 35(12): 2103-2111, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31495881
5.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(12): 2335-2347, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744354
6.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation
; 137(2): 119-129, 2018 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28904068
7.
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Kidney Int
; 96(2): 489-504, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142441
8.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med
; 375(4): 323-34, 2016 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27299675
9.
Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Diabetes Obes Metab
; 21(11): 2465-2473, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297968
10.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
J Am Soc Nephrol
; 29(11): 2755-2769, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30314978
11.
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
JAMA
; 322(12): 1155-1166, 2019 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536101
12.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
JAMA
; 321(1): 69-79, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30418475
13.
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Cardiovasc Diabetol
; 17(1): 39, 2018 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29540217
14.
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Cardiovasc Diabetol
; 16(1): 13, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28109295
15.
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Diabetes Obes Metab
; 19(11): 1610-1619, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28636754
16.
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Diabetologia
; 59(9): 1860-70, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27316632
17.
Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia.
Diabetologia
; 63(11): 2488-2490, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32676817
18.
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Circulation
; 129(5): 587-97, 2014 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24334175
19.
The authors reply.
Kidney Int
; 97(1): 213-214, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31901342
20.
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Am J Kidney Dis
; 66(3): 441-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25960304